Dr Paul Kubler joined the Editorial Executive Committee of Australian Prescriber in 2005 to provide expertise in clinical pharmacology. In 2006 he discovered how controversial medical publishing can be. His first editorial, on patents and evergreening, required the distribution of the journal to be delayed pending legal advice.

Fortunately, the rest of Paul’s time on the Editorial Executive Committee has been less controversial. In 2012 he was appointed as the chair and was excellent in the role.

Paul has provided consistently good clinical advice, particularly about the increasingly complex new drugs which are featured inAustralian Prescriber. Appropriately, Paul finished his time with the journal by writing an article on the Janus kinase inhibitors.

Although he will no longer have to get up at 4 am to attend editorial meetings, the Editorial Executive Committee expects Paul will use the time to write letters to the Editor. His sharp wit and intellect will be missed.Dr Paul Kubler joined the Editorial Executive Committee of Australian Prescriber in 2005 to provide expertise in clinical pharmacology. In 2006 he discovered how controversial medical publishing can be. His first editorial, on patents and evergreening, required the distribution of the journal to be delayed pending legal advice. Fortunately, the rest of Paul’s time on the Editorial Executive Committee has been less controversial. In 2012 he was appointed as the chair and was excellent in the role. Paul has provided consistently good clinical advice, particularly about the increasingly complex new drugs which are featured in Australian Prescriber. Appropriately, Paul finished his time with the journal by writing an article on the Janus kinase inhibitors. Although he will no longer have to get up at 4 am to attend editorial meetings, the Editorial Executive Committee expects Paul will use the time to write letters to the Editor. His sharp wit and intellect will be missed.